{"id":"comparator-vancomycin","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Nephrotoxicity"},{"rate":"1-5%","effect":"Ototoxicity"},{"rate":"10-15%","effect":"Red man syndrome (flushing, pruritus)"},{"rate":"5-10%","effect":"Phlebitis at infusion site"},{"rate":"5%","effect":"Fever"},{"rate":"5%","effect":"Chills"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vancomycin works by binding to the D-alanyl-D-alanine terminus of nascent peptidoglycan in the bacterial cell wall, preventing cross-linking and causing cell wall instability. This leads to bacterial cell lysis and death. It is particularly effective against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).","oneSentence":"Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:11.129Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serious infections caused by susceptible strains of methicillin-resistant Staphylococcus aureus (MRSA)"},{"name":"Clostridium difficile-associated diarrhea and colitis"},{"name":"Endocarditis"},{"name":"Septicemia and other serious gram-positive infections"}]},"trialDetails":[{"nctId":"NCT04781387","phase":"PHASE2","title":"Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection","status":"COMPLETED","sponsor":"Crestone, Inc","startDate":"2021-01-05","conditions":"Clostridioides Difficile Infection","enrollment":43},{"nctId":"NCT07341282","phase":"PHASE2","title":"Investigation of Vancomycin Efficacy in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis","status":"NOT_YET_RECRUITING","sponsor":"McMaster University","startDate":"2026-01","conditions":"Ulcerative Colitis (UC), Primary Sclerosing Cholangitis (PSC)","enrollment":14},{"nctId":"NCT07221370","phase":"PHASE2, PHASE3","title":"Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients","status":"RECRUITING","sponsor":"Riverside University Health System Medical Center","startDate":"2024-10-21","conditions":"Clostridium Difficile Infection, Vancomycin Resistant Enterococci Infection","enrollment":176},{"nctId":"NCT03176134","phase":"PHASE3","title":"A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-01-20","conditions":"Acute Bacterial Skin and Skin Structure Infections","enrollment":100},{"nctId":"NCT04247542","phase":"PHASE2","title":"ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection","status":"COMPLETED","sponsor":"Acurx Pharmaceuticals Inc.","startDate":"2020-03-06","conditions":"Clostridium Difficile Infection","enrollment":53},{"nctId":"NCT02814916","phase":"PHASE3","title":"Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-30","conditions":"Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections","enrollment":199},{"nctId":"NCT03560700","phase":"NA","title":"Probiotic Efficacy in VRE Eradication","status":"COMPLETED","sponsor":"Hvidovre University Hospital","startDate":"2018-06-07","conditions":"VRE Colonization","enrollment":81},{"nctId":"NCT04802837","phase":"PHASE3","title":"Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects","status":"TERMINATED","sponsor":"Summit Therapeutics","startDate":"2021-05-19","conditions":"Clostridioides Difficile Infection","enrollment":2},{"nctId":"NCT01734694","phase":"PHASE4","title":"Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients","status":"TERMINATED","sponsor":"Henry Ford Health System","startDate":"2011-10","conditions":"Health Care Associated Pneumonia, Osteomyelitis/Septic Arthritis, Endocarditis","enrollment":100},{"nctId":"NCT03827447","phase":"PHASE1","title":"Vancomycin for the Treatment of NAAT(+)/Toxin(-) C. Difficile","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2019-07-17","conditions":"Clostridium Difficile Infection","enrollment":7},{"nctId":"NCT02426918","phase":"PHASE2","title":"Study of Debio 1450 for Bacterial Skin Infections","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2015-05","conditions":"Bacterial Infections","enrollment":330},{"nctId":"NCT00269399","phase":"PHASE3","title":"A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2005-12","conditions":"Clostridium Infections, Diarrhea","enrollment":237},{"nctId":"NCT02276482","phase":"PHASE3","title":"Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2015-03-25","conditions":"Skin Diseases, Infectious, Skin Diseases, Bacterial","enrollment":120},{"nctId":"NCT01594827","phase":"PHASE2","title":"Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2012-10","conditions":"Cystic Fibrosis","enrollment":29},{"nctId":"NCT02857582","phase":"PHASE2","title":"Transplantation of Cultured Gut Microflora to Repeat Antibiotic-induced Diarrhea Due to Clostridium Difficile","status":"COMPLETED","sponsor":"Per Hellström","startDate":"2014-10","conditions":"Clostridium Difficile","enrollment":60},{"nctId":"NCT01104662","phase":"PHASE4","title":"Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment","status":"TERMINATED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2010-04-19","conditions":"Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia, Renal Impairment","enrollment":92},{"nctId":"NCT00711802","phase":"PHASE4","title":"Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2008-07-23","conditions":"Skin Diseases, Infectious","enrollment":396},{"nctId":"NCT01728376","phase":"PHASE4","title":"Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2012-11-29","conditions":"Bacteremia","enrollment":82},{"nctId":"NCT01922011","phase":"PHASE3","title":"Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006)","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2013-09-13","conditions":"Acute Hematogenous Osteomyelitis","enrollment":149},{"nctId":"NCT02466698","phase":"PHASE2, PHASE3","title":"Intestinal Lavage for the Treatment of Severe C. Difficile Infections","status":"UNKNOWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2016-08","conditions":"Clostridium Difficile","enrollment":20},{"nctId":"NCT02607618","phase":"PHASE3","title":"Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2","status":"COMPLETED","sponsor":"Motif Bio","startDate":"2015-11","conditions":"Skin Structures and Soft Tissue Infections","enrollment":613},{"nctId":"NCT02600611","phase":"PHASE3","title":"Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1","status":"COMPLETED","sponsor":"Motif Bio","startDate":"2015-11-01","conditions":"Skin Structures and Soft Tissue Infections","enrollment":600},{"nctId":"NCT00428844","phase":"PHASE2","title":"Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2007-06-26","conditions":"Osteomyelitis","enrollment":75},{"nctId":"NCT00770341","phase":"PHASE3","title":"A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-09","conditions":"Staphylococcal Infection","enrollment":122},{"nctId":"NCT00424190","phase":"PHASE3","title":"Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2007-02","conditions":"Bacterial Infections","enrollment":698},{"nctId":"NCT00423657","phase":"PHASE3","title":"Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2007-03","conditions":"Bacterial Infections","enrollment":680},{"nctId":"NCT00445094","phase":"PHASE4","title":"A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-11","conditions":"Infection, Pneumonia","enrollment":120},{"nctId":"NCT02344511","phase":"PHASE3","title":"Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis","status":"WITHDRAWN","sponsor":"Durata Therapeutics International BV (an Affiliate of Actavis, Inc.)","startDate":"2016-03","conditions":"Osteomyelitis","enrollment":""},{"nctId":"NCT01645735","phase":"PHASE4","title":"Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2012-10","conditions":"Infections","enrollment":49},{"nctId":"NCT02307006","phase":"PHASE4","title":"The Use of Ceftaroline as Surgical Prophylaxis in Surgery With Risk of MRSA Infection","status":"UNKNOWN","sponsor":"University of Cincinnati","startDate":"2015-01","conditions":"Surgical Site Infection","enrollment":500},{"nctId":"NCT01669980","phase":"PHASE4","title":"Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2012-10","conditions":"Infections, Pneumonia","enrollment":40},{"nctId":"NCT00772447","phase":"PHASE3","title":"China Registration Study in Patients With Skin Infections","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-09","conditions":"Skin Diseases, Infectious","enrollment":265},{"nctId":"NCT01400867","phase":"PHASE2, PHASE3","title":"Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2011-12","conditions":"Infections, Pediatrics","enrollment":163},{"nctId":"NCT01431339","phase":"PHASE3","title":"Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","startDate":"2011-07","conditions":"Abscess, Wound Infection, Surgical Site Infection","enrollment":739},{"nctId":"NCT01339091","phase":"PHASE3","title":"Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","startDate":"2011-03","conditions":"Abscess, Wound Infection, Surgical Site Infection","enrollment":573},{"nctId":"NCT00210899","phase":"PHASE3","title":"Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Basilea Pharmaceutica","startDate":"2005-09","conditions":"Skin Diseases, Infectious, Skin Diseases, Bacterial, Staphylococcal Skin Infections","enrollment":828},{"nctId":"NCT00228982","phase":"PHASE3","title":"Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Basilea Pharmaceutica","startDate":"2004-10","conditions":"Skin Diseases, Infectious, Skin Diseases, Bacterial, Staphylococcal Skin Infections","enrollment":784},{"nctId":"NCT00430937","phase":"PHASE3","title":"Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-04","conditions":"Skin Diseases, Infectious, Soft Tissue Infections","enrollment":194},{"nctId":"NCT00911573","phase":"PHASE3","title":"Study Evaluating Tigecycline Versus Clindamycin Or Vancomycin On Complicated Skin And Skin Structure Infections Including Those Due To Methicillin-Resistant Staphylococcus Aureus (MRSA) In Pediatric Subjects","status":"WITHDRAWN","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2011-08","conditions":"Skin Diseases, Infection","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10671,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Comparator: vancomycin","genericName":"Comparator: vancomycin","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors. Used for Serious infections caused by susceptible strains of methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile-associated diarrhea and colitis, Endocarditis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}